Orphazyme AS (CHIX:ORPHAC) Net Income From Continuing Operations : kr-596.49 Mil (TTM As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Orphazyme AS's net income from continuing operations for the three months ended in Jun. 2022 was kr-27.30 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2022 was kr-596.49 Mil.

Orphazyme AS Net Income From Continuing Operations Historical Data

The historical data trend for Orphazyme AS's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Net Income From Continuing Operations Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Income From Continuing Operations

Get a 7-Day Free Trial

-131.04

-229.60

-337.50

-633.25

-626.54

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Net Income From Continuing Operations	Get a 7-Day Free Trial									-245.56	-387.69	-57.34	-569.20	-27.30

Orphazyme AS Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-596.49 Mil.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines